Literature DB >> 8414800

Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children.

J C King1, A R Burke, J D Clemens, P Nair, J J Farley, P E Vink, S R Batlas, M Rao, J P Johnson.   

Abstract

Respiratory syncytial virus (RSV) lower respiratory tract and febrile upper respiratory tract illnesses were prospectively assessed in cohorts of 83 infants born to human immunodeficiency virus (HIV)- and of 48 infants born to non-HIV-infected mothers. Of the infants born to HIV-infected mothers, 18 were themselves infected with HIV, 26 were indeterminant and 39 were free from HIV. Ten RSV illnesses occurred in 8 HIV-infected, 2 illnesses in 2 indeterminant and 17 illnesses occurred in 17 non-HIV-infected children. RSV shedding was prolonged in HIV class P2- vs. non-HIV-infected children, at medians of 30 days (range, 1 to 199 days) and 6 days (range, 1 to 21 days), respectively (P = 0.02). Ribavirin and intravenous immunoglobulin failed to eradicate RSV from one child who shed virus for 199 days. Wheezing occurred in 1 of 4 vs. 9 of 10 episodes of lower respiratory tract illness in HIV-infected and non-HIV-infected children, respectively (P = 0.04). No differences were noted in duration of illness, temperature, respiratory rate or oxygen saturation between HIV- and non-HIV-infected children. Infection control and public health concerns regarding prolonged shedding of RSV in HIV-infected children must be recognized.

Entities:  

Mesh:

Year:  1993        PMID: 8414800     DOI: 10.1097/00006454-199309000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  22 in total

Review 1.  Respiratory syncytial virus infection: clinical presentation and management.

Authors:  J A Patel; K Deka; P L Ogra
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

Review 2.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 3.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

Review 4.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 5.  Current research on influenza and other respiratory viruses: II international symposium.

Authors:  F M Munoz; G J Galasso; J M Gwaltney; F G Hayden; B Murphy; R Webster; P Wright; R B Couch
Journal:  Antiviral Res       Date:  2000-05       Impact factor: 5.970

Review 6.  Immunopathological mechanisms in respiratory syncytial virus disease.

Authors:  P J Openshaw
Journal:  Springer Semin Immunopathol       Date:  1995

7.  Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro.

Authors:  T L Gower; B S Graham
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 8.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

9.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

Review 10.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.